EUVIMEDEUVIMED entdecken
Multizentrische Studie

Anti-PD-1 alone or in combination with anti-CTLA-4 for advanced melanoma patients with liver metastases

Ines Pires da Silva, Isabel Li, Selma Ugurel, Patricio Serra-Bellver, Avanti Andhale, Hannah Burnette, Francisco Aya, Jordan W Conway, Jorja Braden, Matteo S Carlino, Alexander M Menzies, Michael Weichenthal und 8 weitere

European Journal of Cancer · 2024

DOI: 10.1016/j.ejca.2024.114101 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift European Journal of Cancer, 2024. Verfasst von Ines Pires da Silva und 19 weiteren Autor:innen. Beteiligte Einrichtung: Melanoma Institute Australia, University of Sydney, Sydney, NSW, Australia; Faculty of Medicine & Health, The University of Sydney, NSW, Australia; C…. Hauptthemen laut MEDLINE: Melanoma, Liver Neoplasms, CTLA-4 Antigen, Programmed Cell Death 1 Receptor. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: Tour de Cure Ltd, NHMRC.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaLiver NeoplasmsCTLA-4 AntigenProgrammed Cell Death 1 ReceptorImmune Checkpoint InhibitorsAntineoplastic Combined Chemotherapy ProtocolsHumansMaleRetrospective StudiesFemaleMiddle AgedAgedAdultAged, 80 and overProgression-Free SurvivalSkin Neoplasms

Stichwörter der Autor:innen

Advanced melanomaAnti-CTLA-4″Anti-PD-(L)1Combination immunotherapyImmunotherapyLiver metastases”Metastatic melanoma

Substanzen

CTLA-4 AntigenProgrammed Cell Death 1 ReceptorImmune Checkpoint InhibitorsCTLA4 protein, humanPDCD1 protein, human

Autor:innen und Institutionen

  • Melanoma Institute Australia, University of Sydney, Sydney, NSW, Australia; Faculty of Medicine & Health, The University of Sydney, NSW, Australia; Charles Perkins Centre, The University of Sydney, NSW, Australia; Crown…
  • Melanoma Institute Australia, University of Sydney, Sydney, NSW, Australia.
  • Department of Dermatology, University Hospital Essen, and German Cancer Consortium (DKTK) partner site Essen/Düsseldorf, Essen, Germany.
  • The Christie NHS Foundation Trust, Manchester, UK.
  • Vanderbilt University Medical Center, Nashville, TN, United States.
  • Department of Medical Oncology, IDIBAPS, Hospital Clínic, Barcelona, Spain.

Förderung

  • Tour de Cure Ltd
  • NHMRC

Zitieren

APA

Pires da Silva, I., Li, I., Ugurel, S., Serra-Bellver, P., Andhale, A., Burnette, H., Aya, F., Conway, J. W., Braden, J., Carlino, M. S., Menzies, A. M., Weichenthal, M., Mohr, P., Gutzmer, R., Arance, A. M., Johnson, D. B., Lorigan, P., Schadendorf, D., Lo, S. N., & Long, G. V. (2024). Anti-PD-1 alone or in combination with anti-CTLA-4 for advanced melanoma patients with liver metastases. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2024.114101

Vancouver

Pires da Silva I, Li I, Ugurel S, Serra-Bellver P, Andhale A, Burnette H, et al. Anti-PD-1 alone or in combination with anti-CTLA-4 for advanced melanoma patients with liver metastases. European Journal of Cancer. 2024. doi:10.1016/j.ejca.2024.114101

BibTeX
@article{PiresdaSilva2024,
  author = {Pires da Silva, Ines and Li, Isabel and Ugurel, Selma and Serra-Bellver, Patricio and Andhale, Avanti and Burnette, Hannah and Aya, Francisco and Conway, Jordan W and Braden, Jorja and Carlino, Matteo S and Menzies, Alexander M and Weichenthal, Michael and Mohr, Peter and Gutzmer, Ralf and Arance, Ana M and Johnson, Douglas B and Lorigan, Paul and Schadendorf, Dirk and Lo, Serigne N and Long, Georgina V},
  title = {Anti-PD-1 alone or in combination with anti-CTLA-4 for advanced melanoma patients with liver metastases},
  journal = {European Journal of Cancer},
  year = {2024},
  doi = {10.1016/j.ejca.2024.114101}
}
Kostenlos starten →